J. Philippé MD, PhD

P76 PrimeFlow™ RNA Assay: a novel technique for single-cell expression analysis in heterogeneous cell populations

Functional exploration of prognostic markers in chronic lymphocytic leukaemia

Summary

A typical hallmark of chronic lymphocytic leukaemia is its clinical heterogeneity, which is reflected by the presence or absence of several prognostic factors, such as cell surface molecules, genetic lesions and microRNAs. Despite having established prognostic value, the functional implications of most of these biomarkers remains poorly defined. The aim of this work was to gain more insight into the role of the B cell receptor and associated prognostic markers ZAP70 and LPL in the biology of chronic lymphocytic leukaemia.

(BELG J HEMATOL 2016;7(5):199–202)

P1.06 Distinguishing leukemic B-lymphoblasts from normal B-cell precursors using cut-off values for expression of CD24, CD38, CD58 and CD66c

Juvenile myelomonocytic leukaemia: the quest for more specific therapies

Summary

Juvenile myelomonocytic leukaemia is a very rare, aggressive stem cell disorder predominantly affecting infants and young children. Current survival rates are disappointing and the only available curative therapy is haematopoietic stem cell transplantation. Over the last years, intensive research efforts elucidated a plethora of molecular aberrations involved in the pathogenesis of juvenile myelomonocytic leukaemia. Current investigations are mainly directed towards the complete unravelling of the molecular biology behind the disease in order to find more specific drugs. This review will focus on the diagnosis, genomic characterisation and the use of experimental therapies in juvenile myelomonocytic leukaemia.

(BELG J HEMATOL 2014; 5(4): 119–24)

P4.13 CMYB expression during in vitro hematopoiesis from human embryonic stem cells